3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
2
Wilms Tumor
1
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pseudomyxoma Peritonei
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Melanoma
1
Lymphoma, B-Cell
1
Lymphoma
1
Kidney Transplantation
1
Digestive System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Burkitt Lymphoma
1
Adenocarcinoma, Clear Cell
1
Interventions
Cyclophosphamide
103
fludarabine
61
Methotrexate
49
Dexamethasone
46
fludarabine phosphate
45
Cytarabine
45
Vincristine
42
blinatumomab
36
Whole-Body Irradiation
33
Mycophenolic Acid
30
Tacrolimus
26
Mercaptopurine
26
Melphalan
26
venetoclax
24
Specimen Handling
24
Etoposide
23
Peripheral Blood Stem Cell Transplantation
21
pegaspargase
20
Stem Cell Transplantation
19
Granulocyte Colony-Stimulating Factor
19
Calcium Dobesilate
19
Busulfan
19
Doxorubicin
18
Prednisone
17
Rituximab
16
Filgrastim
16
Daunorubicin
16
Asparaginase
16
merphos
15
Thiotepa
15
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma
×
Alemtuzumab
×
1 year
×
Clear all
NCT03821610
2026-05-05
ALL-RIC
University of Birmingham
Phase 2
Active not recruiting
242 enrolled